{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:07:02Z","timestamp":1761440822455,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,25]]},"DOI":"10.7759\/cureus.95407","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:03:26Z","timestamp":1761440606000},"source":"Crossref","is-referenced-by-count":0,"title":["A Self-Reported Survey-Based Evaluation of the Real-World Effectiveness of Non-mRNA COVID-19 Vaccines During the Second Pandemic Wave in India"],"prefix":"10.7759","author":[{"given":"Subeikshanan","family":"Venkatesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrutha Bindu","family":"Nagella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukumar","family":"Kalvapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshat","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ajith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishab","family":"Belavadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiksha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh S","family":"Madhugiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072","article-title":"COVID-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk M","year":"2021","unstructured":"Bergwerk M, Gonen T, Lustig Y, et al.. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021, 385:1474-84. 10.1056\/NEJMoa2109072","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/v13091782","article-title":"Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India","volume":"13","author":"Gupta N","year":"2021","unstructured":"Gupta N, Kaur H, Yadav PD, et al.. Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India. Viruses. 2021, 13:1782. 10.3390\/v13091782","journal-title":"Viruses"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch M","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022, 22:57-65. 10.1038\/s41577-021-00662-4","journal-title":"Nat Rev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi EK","year":"2022","unstructured":"Accorsi EK, Britton A, Fleming-Dutra KE, et al.. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022, 327:639-51. 10.1001\/jama.2022.0470","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar","volume":"386","author":"Abu-Raddad LJ","year":"2022","unstructured":"Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al.. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022, 386:1804-16. 10.1056\/NEJMoa2200797","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin DR","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, et al.. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022, 399:924-44. 10.1016\/S0140-6736(22)00152-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00729-0","article-title":"Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study","volume":"23","author":"Powell AA","year":"2023","unstructured":"Powell AA, Kirsebom F, Stowe J, Ramsay ME, Lopez-Bernal J, Andrews N, Ladhani SN. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Lancet Infect Dis. 2023, 23:435-44. 10.1016\/S1473-3099(22)00729-0","journal-title":"Lancet Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Clemens SA, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella R","year":"2021","unstructured":"Ella R, Reddy S, Blackwelder W, et al.. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021, 398:2173-84. 10.1016\/S0140-6736(21)02000-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42210","article-title":"SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi, India","volume":"5","author":"Malhotra S","year":"2022","unstructured":"Malhotra S, Mani K, Lodha R, et al.. SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi, India. JAMA Netw Open. 2022, 5:e2142210. 10.1001\/jamanetworkopen.2021.42210","journal-title":"JAMA Netw Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/25151355231181744","article-title":"Clinico-epidemiological profile and outcome of infected health care workers during the three consecutive waves of COVID-19 pandemic: a longitudinal cohort study","volume":"11","author":"Mathew M","year":"2023","unstructured":"Mathew M, Sebastian J, Doddaiah N, Thomas A, Narayanappa S. Clinico-epidemiological profile and outcome of infected health care workers during the three consecutive waves of COVID-19 pandemic: a longitudinal cohort study. Ther Adv Vaccines Immunother. 2023, 11:25151355231181744. 10.1177\/25151355231181744","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2023-0017","article-title":"Severity and outcome of post-vaccine COVID-19 among healthcare workers in a university hospital in India","volume":"16","author":"Vishnoi J","year":"2023","unstructured":"Vishnoi J, Sharma RK, Patel J, Sharma JC, Sharma KR, Mehta U. Severity and outcome of post-vaccine COVID-19 among healthcare workers in a university hospital in India. J Med Life. 2023, 16:782-93. 10.25122\/jml-2023-0017","journal-title":"J Med Life"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276759","article-title":"Effectiveness of COVID-19 vaccines (CovishieldTM and Covaxin \u00ae) in healthcare workers in Mumbai, India: a retrospective cohort analysis","volume":"17","author":"Contractor A","year":"2022","unstructured":"Contractor A, Shivaprakash S, Tiwari A, Setia MS, Gianchandani T. Effectiveness of COVID-19 vaccines (CovishieldTM and Covaxin \u00ae) in healthcare workers in Mumbai, India: a retrospective cohort analysis. PLoS One. 2022, 17:e0276759. 10.1371\/journal.pone.0276759","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58860","article-title":"Breakthrough COVID-19 infection among the general community, frontline workers, and healthcare workers during the second and third wave in North India: a longitudinal study","volume":"16","author":"Chaudhary A","year":"2024","unstructured":"Chaudhary A, Bansal P, Satija M, et al.. Breakthrough COVID-19 infection among the general community, frontline workers, and healthcare workers during the second and third wave in North India: a longitudinal study. Cureus. 2024, 16:e58860. 10.7759\/cureus.58860","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2022.09.010","article-title":"Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: a retrospective observational study from a cancer hospital in eastern India","volume":"41","author":"Bhattacharya S","year":"2023","unstructured":"Bhattacharya S, Chatterji S, Chandy M, et al.. Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: a retrospective observational study from a cancer hospital in eastern India. Indian J Med Microbiol. 2023, 41:104-10. 10.1016\/j.ijmmb.2022.09.010","journal-title":"Indian J Med Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100361","article-title":"Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN\u00ae) and ChAdOx1 nCoV-19 (COVISHIELD\u2122) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study","volume":"22","author":"Asokan MS","year":"2024","unstructured":"Asokan MS, Joan RF, Babji S, et al.. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN\u00ae) and ChAdOx1 nCoV-19 (COVISHIELD\u2122) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study. Lancet Reg Health Southeast Asia. 2024, 22:100361. 10.1016\/j.lansea.2024.100361","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pecinn.2023.100167","article-title":"Breakthrough infections and acceptance of COVID-19 vaccine boosters: a survey analysis","volume":"2","author":"Stevens CW","year":"2023","unstructured":"Stevens CW, Neely SR, Scacco JM. Breakthrough infections and acceptance of COVID-19 vaccine boosters: a survey analysis. PEC Innov. 2023, 2:100167. 10.1016\/j.pecinn.2023.100167","journal-title":"PEC Innov"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091435","article-title":"Dynamics of trust and consumption of COVID-19 information implicate a mechanism for COVID-19 vaccine and booster uptake","volume":"10","author":"Juarez R","year":"2022","unstructured":"Juarez R, Kang Z, Okihiro M, Garcia BK, Phankitnirundorn K, Maunakea AK. Dynamics of trust and consumption of COVID-19 information implicate a mechanism for COVID-19 vaccine and booster uptake. Vaccines (Basel). 2022, 10:1435. 10.3390\/vaccines10091435","journal-title":"Vaccines (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu B","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021, 19:141-54. 10.1038\/s41579-020-00459-7","journal-title":"Nat Rev Microbiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_957_20","article-title":"Clinical management of COVID-19","volume":"151","author":"Varghese GM","year":"2020","unstructured":"Varghese GM, John R, Manesh A, Karthik R, Abraham OC. Clinical management of COVID-19. Indian J Med Res. 2020, 151:401-10. 10.4103\/ijmr.IJMR_957_20","journal-title":"Indian J Med Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study","volume":"397","author":"Hall VJ","year":"2021","unstructured":"Hall VJ, Foulkes S, Saei A, et al.. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021, 397:1725-35. 10.1016\/S0140-6736(21)00790-X","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.05.018","article-title":"The current second wave and COVID-19 vaccination status in India","volume":"96","author":"Chakraborty C","year":"2021","unstructured":"Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The current second wave and COVID-19 vaccination status in India. Brain Behav Immun. 2021, 96:1-4. 10.1016\/j.bbi.2021.05.018","journal-title":"Brain Behav Immun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study","volume":"22","author":"Menni C","year":"2022","unstructured":"Menni C, May A, Polidori L, et al.. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022, 22:1002-10. 10.1016\/S1473-3099(22)00146-3","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Costa Clemens SA, Madhi SA, et al.. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021, 397:881-91. 10.1016\/S0140-6736(21)00432-3","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson MG","year":"2021","unstructured":"Thompson MG, Burgess JL, Naleway AL, et al.. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021, 385:320-9. 10.1056\/NEJMoa2107058","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.08.21259776","article-title":"Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States","author":"Tenforde MW","year":"2021","unstructured":"Tenforde MW, Patel MM, Ginde AA, et al.. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. medRxiv. 2021, 10.1101\/2021.07.08.21259776","journal-title":"medRxiv"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam A","year":"2022","unstructured":"Singanayagam A, Hakki S, Dunning J, et al.. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022, 22:183-95. 10.1016\/S1473-3099(21)00648-4","journal-title":"Lancet Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi SA","year":"2021","unstructured":"Madhi SA, Koen AL, Izu A, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial. Lancet HIV. 2021, 8:e568-80. 10.1016\/S2352-3018(21)00157-0","journal-title":"Lancet HIV"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.143","article-title":"Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant","volume":"3","author":"Zhou Z","year":"2022","unstructured":"Zhou Z, Du P, Li N, et al.. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. MedComm (2020). 2022, 3:e143. 10.1002\/mco2.143","journal-title":"MedComm (2020)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2244","article-title":"Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study","volume":"374","author":"Hippisley-Cox J","year":"2021","unstructured":"Hippisley-Cox J, Coupland CA, Mehta N, et al.. Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ. 2021, 374:n2244. 10.1136\/bmj.n2244","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371231-a-self-reported-survey-based-evaluation-of-the-real-world-effectiveness-of-non-mrna-covid-19-vaccines-during-the-second-pandemic-wave-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:03:27Z","timestamp":1761440607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371231-a-self-reported-survey-based-evaluation-of-the-real-world-effectiveness-of-non-mrna-covid-19-vaccines-during-the-second-pandemic-wave-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.95407","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}